Title |
Pharmacokinetics and Pharmacodynamics of Nonsteroidal Androgen Receptor Ligands
|
---|---|
Published in |
Pharmaceutical Research, July 2006
|
DOI | 10.1007/s11095-006-9024-3 |
Pubmed ID | |
Authors |
Wenqing Gao, Juhyun Kim, James T. Dalton |
Abstract |
Testosterone and structurally related anabolic steroids have been used to treat hypogonadism, muscle wasting, osteoporosis, male contraception, cancer cachexia, anemia, and hormone replacement therapy in aging men or age-related frailty; while antiandrogens may be useful for treatment of conditions like acne, alopecia (male-pattern baldness), hirsutism, benign prostatic hyperplasia (BPH) and prostate cancer. However, the undesirable physicochemical and pharmacokinetic properties of steroidal androgen receptor (AR) ligands limited their clinical use. Nonsteroidal AR ligands with improved pharmacological and pharmacokinetic properties have been developed to overcome these problems. This review focuses on the pharmacokinetics, metabolism, and pharmacology of clinically used and emerging nonsteroidal AR ligands, including antagonists, agonists, and selective androgen receptor modulators. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Mexico | 1 | 1% |
Unknown | 79 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 17 | 21% |
Researcher | 9 | 11% |
Student > Bachelor | 8 | 10% |
Student > Master | 7 | 9% |
Student > Doctoral Student | 5 | 6% |
Other | 15 | 19% |
Unknown | 20 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 20 | 25% |
Chemistry | 11 | 14% |
Agricultural and Biological Sciences | 10 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
Biochemistry, Genetics and Molecular Biology | 4 | 5% |
Other | 5 | 6% |
Unknown | 25 | 31% |